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participating centers in Europe and Canada identiﬁed 36 patients with
SAA who underwent TAVI with the 20mm SXT THV. Baseline and
post-procedural clinical and echocardiographic outcomes were
assessed.
RESULTS Mean age was 846 yrs, with a strong female preponder-
ance (94%). The median (IQR) STS score was 8.7 (5.4, 12.2) %. Baseline
mean aortic gradient, median (IQR) aortic valve area and mean
annular dimensions were 49.517.6 mmHg, 0.50 (0.40, 0.60) cm2 and
18.51.6 mm respectively. Fifteen patients (42%) had a pre-existing
aortic bioprosthesis measuring 19 (n¼6), 21 (n¼8) and 23 (n¼1) mm,
and these patients subsequently underwent valve-in-valve TAVI. The
mean aortic annular diameter, as measured with computed tomog-
raphy, in patients with native AS was 19.11.4 mm. A transfemoral
approach was undertaken in 92% of cases, with successful implanta-
tion in all but 2 patients (6%), with no reports of procedural death,
annular rupture or need for a second valve. Balloon post-dilatation
occurred in 11% of cases. The incidences of in-hospital stroke, major
vascular complication or death were 3, 11, and 6%, respectively.
Overall, post-procedural mean transprosthetic gradient and median
(IQR) valve areas were 17.78.1 mmHg and 1.10 (0.95, 1.30) cm2,
respectively [native AS: 13.25.0 mmHg and 1.22 (1.15, 1.55) cm2;
valve-in-valve: 24.07.5 mmHg and 0.98 (0.77, 1.10) cm2]. Moderate
paravalvular regurgitation was evident in 1 patient.
CONCLUSIONS In patients with severe AS and SAA, TAVI with the
20mm SXT THV is technically feasible, providing satisfactory early
clinical and hemodynamic results, with native valve TAVI yielding
lower post-procedural gradients compared with valve-in-valve TAVI.
Longer-term follow-up in a larger cohort, with clinical and hemody-
namic comparisons against larger THV sizes implanted in corre-
spondingly larger aortic annuli will be necessary to truly ascertain the
feasibility of TAVI in severe AS patients with SAA.
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BACKGROUND Incidence of rhythm changes and permanent pace-
maker implantation post TAVI are variable and may differ depending
on the device type. This report evaluates the incidence and associated
circumstances of the rhythm disturbances observed with the St Jude
Medical Portico Self Expanding TAVI system.
METHODS Rhythm information was collected as part of a prospective,
single arm, multicenter study. Between December 2011 and May 2015,
198 TAVI patients were enrolled and treated at 12 sites in the UK,
Germany, Netherlands, Denmark and Australia using the 18F and 19F
Portico system with a 23mm (50), 25mm (50), 27mm (60) or 29mm (38)
valve size. Rhythm changes during the procedure were recorded at
baseline and at key steps during the implant procedure. Rhythm was
recorded prior to wire passage through the valve, prior to pre-dilata-
tion, immediately post-dilatation, prior to valve crossing, post valve
deployment and at the end of the procedure. Rhythm was recorded
during recovery and at all follow-up intervals.
RESULTS All 198 patients were successfully treated with the Portico
system. The most common rhythm disturbances at baseline were AF
(20%), LBBB (4%), and RBBB (2.5%). A total of 24 patients required a
permanent pacemaker (PPM) post procedure, with complete heart
block as the predominant reason (96%). Depth of implant, valve
resheathing or post dilatation did not appear to impact on the need for
PPM. There were 23 patients (13.5%) who developed a new LBBB
during the procedure, with the majority occurring before valvedeployment (73.9%). An additional 18 patients (11.1%) developed
LBBB before discharge.
CONCLUSIONS The Portico TAVI system demonstrated a low rate of
PPM implantation and induction of new LBBB post TAVI. There does
not appear to be a consistent cause intra-operatively and further
analysis is necessary to understand this phenomenon.
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BACKGROUND Most centers perform transcatheter aortic valve im-
plantation TAVI under general anesthesia (GA) or deep sedation (DS).
TAVI under local anesthesia (LA) might result in less periprocedural
episodes of hypotension, shorter procedure time and hospital stay.
The aim of this study was to compare feasibility and clinical outcome
after TAVI under LA using the self-expandable 18-F-CoreValve pros-
thesis (MCV) versus the 14-20F-balloon expandable Edwards Sapien
XT/3 prosthesis (ESV).
METHODS Between April 2010 and October 2014, 570 consecutive pts
underwent successfully transfemoral TAVI in LA exclusively without
GA or DS receiving either MCV (23/26/29/31mm) or the ESV
(23,26,29mm). Clinical events were evaluated according to the VARC-
II criteria.
RESULTS Patients: 361 pts (age 80.60.34 years) with severe AS
(pmean 43.10.77 mmHg, AVA 0.68  0.01 cm2) and high surgical risk
(log Euroscore 22.0 0.67 %) underwent successfully TAVI with the
MCV and 209 pts (age 81.70.41 years, log Euroscore 18.60.82 %,
pmean 44.21.12 mmHg, AVA 0.68  0.02 cm2) received the ESV
Procedural outcome: Device success was 357/361 (98.9%) for MCV and
208/209 (99.5%) for ESV. Conversion to GA occurred in only 4/361
MCV pts., exclusively for complication (1 coronary obstruction, 2 se-
vere AR, 1 prosthesis embolisation with urgent surgery) and in 0 pts
after ESV. Conversion to DS occurred in 16/361 (4.4%) MCV pts. and in
5/209 (2.4%) ESV pts. Use of vasopressors were needed in 19/361
(5.2%) MCV pts. and in 6/209 (2.9%) ESV pts. In-lab-death and In-lab
stroke rate was 0% in both groups. 30-day clinical outcome: 30 day all-
cause mortality and major/minor stroke rate did not differ signiﬁ-
cantly between valves (death: MCV vs ESV: 5.5% vs 2.4%;
p¼0.052;major stroke: MCV vs ESV: 0.8% vs. 2.4%; P¼0.273. minor
stroke: MCV vs ESV: 0.8% vs. 0.5; p¼0.273.). There was no signiﬁcant
difference between the two valve types concerning major vascular
complication (MCV vs ESV: 4.7% vs. 7.9%; p¼0.082. The rate of new
pacemaker implantation was signiﬁcantly different (MCV vs ESV:
24.4% vs 14.4%, p<0.01).
CONCLUSIONS Transfemoral TAVI using LA only is feasible and save
in an all-comer TAVI-population using either selfexpandable or
balloon-expandable transcatheter heart valves.
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BACKGROUND Transfemoral aortic valve implantation (TAVI) re-
quires large bore catheters. Access site and vascular complications,
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TAVI pseudoaneurysm formation (PAF) is a frequent minor vascular
complication. The aim of the study was to compare the incidence of
post-TAVI PAF between the CoreValve (CV) using the St.Jude 18-F-
sheath, the Edwards Sapien XT valve (ESV-XT) using the 16-20 F
Esheath and the Edwards Sapien 3 (EDV-3) with the 14-16 f sheath.
METHODS Between April 2010 and October 2013, 574 pts (age 81.6 
0.41years) with high surgical risk (Euroscore 18.5 0.86%) underwent
successfully TAVI in local anesthesia using either the CV
(23,26,29,31mm), the ESVXT (23, 26, 29mm) or the ESV3 (23, 26,
29mm). Closure of the access site was performed in all pts by using the
ProStar XL 10 suture device. All TAVI pts (361 CV, 106 ESV-XT and 107
ESV-3) were examined serially the ﬁrst 5 days (day 1-3 and 5 post-
TAVI) after the procedure by ultrasound (US) for clinically silent
vascular complications. In case of PAF, ultrasound-guided manual
compression was done followed by compression bandage for another
24 h.
RESULTS In 34 pts (5.9%) we observed major vascular complication
after TAVI (17 [4.7 %] after CV, 7 [6.6%] after ESV-XT and 10 [9.3%]
after ESV-3, p¼0.076). In 123 pts (21.4%) we observed post-TAVI PAF,
which occurred signiﬁcantly more frequently after implantation of the
ESV-XT and ESV-3 than after implantation of the CV. CV versus ESV-
XT versus ESV-3 (60/361 [16.6%] versus 32/106 [30.2%] versus 31/107
[28.9%], p1¼0.01, p2¼0.002 and p3¼0.001). However in total only 8/
123 (6.1 %) patients with PAFs had to be treated surgically, the others
were treated either by ultrasound guided manual compression or
conservatively if smaller than 1 cm.
CONCLUSIONS Clinically silent PAF detected by routine US is a
frequent post-TAVI minor vascular complication which is more likely
to occur after ESV-XT and ESV-3 using the Esheath than after CV.
Although US-guided compression is highly effective, further minia-
turisation of TAVI devices and modiﬁcation of the Esheath design
might help to eliminate post-TAVI PAF.
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BACKGROUND The signiﬁcance of aortic regurgitation (AR) pre-
transcatheter aortic valve implantation (TAVI) implantation is un-
known. The present study aimed to assess the clinical repercussion of
AR in patients undergoing TAVI.
METHODS Retrospective analysis of 150 patients (mean age 817
years old, 43% male), from a tertiary centre prospective registry of 185
consecutive TAVI procedures, between November 2008 and
November 2014. The indication for TAVI was, aortic stenosis in 145
pts, degenerated biologic prosthetic valve in 3 pts and homograft
dysfunction in 2 pts. AR was found in 122 (75%) pts and was moderate
to severe in 33 (22%). We evaluated the clinical differences ate the
presentation and at a median follow up of 22 IQ [2-38] months,
stratiﬁed by the presence of moderate to severe AR, using the
following tests: Qui2, t-student and Mann- Withney.
RESULTS Patients with moderate to severe AR presented more
frequently with a NYHA functional class IV (21% vs 8.5%, p¼0.04) and
with a higher median NT-ProBNP (5190 IQ [1041-11457]pg/ml vs 1765
[795-3632] pg/ml, p¼0.02). During the follow up, they showed a greater
decrease of NT-proBNP (3295 IQ [1082-9621]pg/ml vs 1329 [267-2018]
pg/ml, p¼0.004) and a higher incidence of moderate to severe leak
(24% vs 8%, p ¼ 0.02). The incidence of leak in the overall population
was 65%, being moderate to severe in 16 pts (11%). In pts with leak, the
presence of pre-TAVI moderate to severe AR was associated with a
higher baseline NYHA functional class (p¼0.03) and with a more sig-
niﬁcant functional improvement (> 2 NYHA stages) during the follow
up (p¼0.04). The presence of AR was not associated with 30-day and 1-
year mortality. Seven pts with moderate to severe AR developed
moderate to severe leak. There was no differences between these pts
and the overall population, in what concerns to functional class, NT-
proBNP and cardiovascular events during the follow up.CONCLUSIONS Patients with moderate to severe aortic regurgitation
have a worse baseline clinical status and improve more signiﬁcantly
after transcatheter aortic valve implantation. The presence of AR was
associated with higher incidence of moderate to severe leak without
signiﬁcant clinical repercussion.
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BACKGROUND Transcatheter aortic valve implantation (TAVI) is the
treatment of choice for patients (pts) with severe symptomatic aortic
stenosis (AS) with high surgical risk. Many of these pts present with
chronic renal failure (CRF) or end-stage renal disease (ESRD). Chronic
and acute kidney injury might affect survival after TAVI though cur-
rent data is inconsistent. The aim of this study was to evaluate acute
kidney injury (AKI III) after TAVI under local anesthesia using either
the self-expandable 18-F-CoreValve prosthesis (MCV) or the 14-20F-
balloon expandable Edwards Sapien XT/3 prosthesis (ESV) in relation
to the pre-existent renal function and its association to clinical
outcome.
METHODS Between April 2010 and October 2014, 572 consecutive pts
(age 81.0  0.3years, 281 female) underwent successfully transfemoral
TAVI using either MCV or ESV in local anesthesia exclusively without
general anesthesia or deep sedation. Clinical events and acute kidney
injury (AKI) were evaluated according to the VARC-II criteria.
RESULTS Patients: 334 (58.4%) pts presented with NRF, 221 (38.6 %)
patients with CRF and 17 (2.97 %) pts with end-stage renal disease.
AKI III was 10.6 times higher in the CRF group than in the NRF
group: NRF vs CRF: 0.3% vs 3.2%, p> 0.01. 30-day clinical outcome:
30 day all-cause mortality differed signiﬁcantly between pts with
NRF and CRF and was highest in the ESRD group. NRF: 2.7%; CRF:
5.0%; ESRD: 23.5%). 30 day stroke rate was not signiﬁcantly
enhanced in pts with CRF or ESRD compared to pts with NRF. ( NRF
2.1 % ; CRF 2.3 % ; ESRD 0 %). Long-term clinical outcome: Longterm
mortality differed also signiﬁcantly beween the three groups: NRF
15.3 %; CRF 28.3 %; ESRD 58.8%). In contrast to 30 day-stroke rate,
long-term stroke was highest in the ESRD group. NRF 8.1 %; CRF 5.9
%; ESRD 17.6%. A multivariate analysis including atrial ﬁbrillation,
log Euroscore, age, sex, ejection fraction, type of valve (MCV or
ESV), AKN III and CRF, showed that only CRF represents an inde-
pendent predictor for 30 day mortality.
CONCLUSIONS Chronic and acute kidney injury is associated with
higher 30-day and longterm mortality, being highest in pts with ESRD.
TAVi should be indicated cautiously in patients with ESRD.
CATEGORIES STRUCTURAL: Valvular Disease: Aortic
KEYWORDS Acute kidney injury, Renal insufﬁciency, chronic, TAVR
TCT-643
Platelet activation is less enhanced in the new balloon expandable
Edwards Sapien 3 valve compared to its predecessor model (Edwards
Sapien XT) and is associated to the extent of residual aortic regurgitation
Suzanne Fateh-Moghadam,1 Sabrina Voesch,2 Tobias Geisler,3
Meinrad Gawaz,4 Wolfgang Bocksch5
1UC Tuebingen, Tuebingen, Germany; 2Eberhard-Karls University of
Tuebingen, tuebingen, BW; 3University Hospital Tübingen, Dept.
Cardiology, Tübingen, Germany; 4University Hospital Tübingen,
Department of Cardiology, Tübingen, BW; 5Eberhard-karls-Universität
Tübingen, Tubingen, Germany
BACKGROUND Due to a different design of the Cobalt chromium alloy
frame, the additional outerskirt to minimize paravalvular leakage and
the thinner struts of the stent frame, one might imagine that the
extent of platelet activation (PA) of the new Edwards Sapien 3 valve
(ESV3) might differ from the Edward Sapien XT valve (ESVXT).
Furthermore paravalvular leaks and hence residual aortic regurgita-
tion should be substantionally reduced The aim of our study was to
compare platelet aggregation (Agg) and platelet activation (PA)
observed with two different catheter valves, the ESV-XT and the
